Journal of Biological Chemistry · 2005 · 52 citations · 25 references
Life SciencesBiochemistryMolecular BiologyCell SignalingSignal TransductionStructural BiologyAngiogenesisCalcium-binding ProteinsGrowth Factor SignalingVenom BiologyCalcium Binding DomainsMyotoxic EnvenomationPlatelet-derived Growth Factor InhibitionPlatelet-derived Growth Factor ReceptorsSnake Venom ToxicologyVascular Endothelial Growth FactorVascular Endothelial Growth Factor ReceptorsVenom Pharmacology
Vascular endothelial growth factor (VEGF165) and its receptor KDR (kinase insert domain-containing receptor) are central regulators of blood vessel formation. We herein report a KDR-binding protein we have isolated in the venom of eastern cottonmouth (Agkistrodon piscivorus piscivorus). Sequence analysis revealed the isolated KDR-binding protein (designated KDR-bp) is identical to Lys49-phosholipase A2 (Lys49PLA2), an inactive PLA2 homologue with strong myotoxicity, in which Lys49 substitutes Asp49, a key residue for binding the essential cofactor Ca2+. KDR-bp binds to the extracellular domain of KDR with subnanomolar affinity. KDR-bp also binds to a lesser extent with Flt-1 and IgG but not to other receptors with similar immunoglobulin-like domain structures such as platelet-derived growth factor receptor α. The interaction between KDR-bp and KDR was blocked by VEGF165, and KDR-bp specifically inhibited VEGF165-stimulated endothelial cell proliferation, indicating KDR-bp is an antagonistic ligand for KDR. Lys49PLA2s from another snake venom were found to exhibit similar receptor binding properties to KDR-bp. This is the first report to demonstrate that an exogenous factor antagonizes VEGF and its receptor system. Our observation offers further insight into the as yet unknown molecular mechanism of myotoxic activity of snake venom Lys49PLA2s. Furthermore, KDR-bp would make a valuable tool for studying the structure and function of KDR, such as that expressed on skeletal muscle cells. Vascular endothelial growth factor (VEGF165) and its receptor KDR (kinase insert domain-containing receptor) are central regulators of blood vessel formation. We herein report a KDR-binding protein we have isolated in the venom of eastern cottonmouth (Agkistrodon piscivorus piscivorus). Sequence analysis revealed the isolated KDR-binding protein (designated KDR-bp) is identical to Lys49-phosholipase A2 (Lys49PLA2), an inactive PLA2 homologue with strong myotoxicity, in which Lys49 substitutes Asp49, a key residue for binding the essential cofactor Ca2+. KDR-bp binds to the extracellular domain of KDR with subnanomolar affinity. KDR-bp also binds to a lesser extent with Flt-1 and IgG but not to other receptors with similar immunoglobulin-like domain structures such as platelet-derived growth factor receptor α. The interaction between KDR-bp and KDR was blocked by VEGF165, and KDR-bp specifically inhibited VEGF165-stimulated endothelial cell proliferation, indicating KDR-bp is an antagonistic ligand for KDR. Lys49PLA2s from another snake venom were found to exhibit similar receptor binding properties to KDR-bp. This is the first report to demonstrate that an exogenous factor antagonizes VEGF and its receptor system. Our observation offers further insight into the as yet unknown molecular mechanism of myotoxic activity of snake venom Lys49PLA2s. Furthermore, KDR-bp would make a valuable tool for studying the structure and function of KDR, such as that expressed on skeletal muscle cells. Vascular endothelial growth factor (VEGF165) 1The abbreviations used are: VEGF, vascular endothelial growth factor; Flt-1, fms-like tyrosine kinase-1; KDR, kinase insert domain-containing receptor; KDR-bp, KDR-binding protein; PLA2, phospholipase A2; Tf PLA2, Asp49PLA2 from the venom of Trimeresurus flavoviridis; TIMP, tissue inhibitor of metalloproteinase; PDGF, platelet-derived growth factor; FGF, fibroblast growth factor. and its receptor system play a central role in the angiogenic process (1Ferrara N. Endocr. Rev. 2004; 25: 581-611Crossref PubMed Scopus (2984) Google Scholar). The physiological significance of this system has been established in several reports which show that genetic deficiency of either ligand or receptor results in embryonic lethality because of failed vasculature development. VEGF165 binds to two well characterized receptors on endothelial cells, namely fms-like tyrosine kinase-1 (Flt-1, VEGF receptor 1) and kinase insert domain-containing receptor (KDR, VEGF receptor 2). Flt-1 and KDR have highly homologous features related to the receptor tyrosine kinase family; both receptors are comprised of a seven-tandem extracellular immunoglobulin-like domain, a transmembrane domain, and a cytoplasmic tyrosine kinase domain. Several studies show the second and third domains are ligand-binding domains in both receptors (2Wiesmann C. Fuh G. Christinger H.W. Eigenbrot C. Wells J.A. de Vos A.M. Cell. 1997; 91: 695-704Abstract Full Text Full Text PDF PubMed Scopus (415) Google Scholar, 3Shinkai A. Ito M. Anazawa H. Yamaguchi S. Shitara K. Shibuya M. J. Biol. Chem. 1998; 273: 31283-31288Abstract Full Text Full Text PDF PubMed Scopus (138) Google Scholar), indicating similar ligand-receptor binding. VEGF165 is an antiparallel homodimer, covalently linked by two disulfide bridges. It has been shown that one VEGF165 dimer binds two molecules of receptor, indicating the dimer ligand causes receptor dimerization following receptor activation (4Fuh G. Li B. Crowley C. Cunningham B. Wells J.A. J. Biol. Chem. 1998; 273: 11197-11204Abstract Full Text Full Text PDF PubMed Scopus (237) Google Scholar). To date, several trials have attempted to find antagonizing molecules for VEGF-VEGF receptor interaction (5Ferrara N. Oncologist. 2004; 9: 2-10Crossref PubMed Scopus (515) Google Scholar), including monoclonal antibodies, soluble receptors, peptides, siRNA, and several small synthetic inhibitors. The only physiological inhibitor of this interaction reported is tissue inhibitor of metalloproteinase-3 (TIMP-3) (6Qi J.H. Ebrahem Q. Moore N. Murphy G. Claesson-Welsh L. Bond M. Baker A. Anand-Apte B. Nat. Med. 2003; 9: 407-415Crossref PubMed Scopus (545) Google Scholar). TIMP-3 directly binds to the extracellular domain of KDR and blocks the angiogenic activity of VEGF165 with subnanomolar affinity (6Qi J.H. Ebrahem Q. Moore N. Murphy G. Claesson-Welsh L. Bond M. Baker A. Anand-Apte B. Nat. Med. 2003; 9: 407-415Crossref PubMed Scopus (545) Google Scholar). Snake venoms are a plentiful source of several interesting molecules possessing unique biological activities that are never seen in mammals. Recently, two novel VEGFs, designated VEGF-F, have been isolated and characterized from viper venoms (7Yamazaki Y. Takani K. Atoda H. Morita T. J. Biol. Chem. 2003; 278: 51985-51988Abstract Full Text Full Text PDF PubMed Scopus (98) Google Scholar). These snake venom-derived VEGFs exhibit strict receptor selectivity compared with other known VEGF subtypes; they specifically recognize KDR but do not recognize any other known VEGF receptors (7Yamazaki Y. Takani K. Atoda H. Morita T. J. Biol. Chem. 2003; 278: 51985-51988Abstract Full Text Full Text PDF PubMed Scopus (98) Google Scholar). The crystal structures of both proteins display similar but markedly distinct features from other known VEGFs, including the structure of receptor-binding loop and the surface potential (8Suto K. Yamazaki Y. Morita T. Mizuno H. J. Biol. Chem. 2005; 280: 2126-2131Abstract Full Text Full Text PDF PubMed Scopus (83) Google Scholar). In this study, we report that myotoxic basic phospholipase A2 (Lys49PLA2) obtained from the venom of eastern cottonmouth binds the extracellular domain of KDR with subnanomolar affinity and results in the blockage of VEGF165. Lys49PLA2s are widespread in the venom of several vipers and are structurally classified as group II PLA2s, although the molecular mechanism of their myotoxicity remains unknown (9Lomonte B. Angulo Y. Calderon L. Toxicon. 2003; 42: 885-901Crossref PubMed Scopus (260) Google Scholar, 10Gutierrez J.M. Ownby C.L. Toxicon. 2003; 42: 915-931Crossref PubMed Scopus (333) Google Scholar). Despite significant homology to active PLA2s, Lys49PLA2s are inactive phospholipolytic enzymes because the Lys49 substitutes Asp49, a key residue for binding of the essential Ca2+-cofactor (11Ward R.J. Chioato L. de Oliveira A.H. Ruller R. Sa J.M. Biochem. J. 2002; 362: 89-96Crossref PubMed Scopus (78) Google Scholar). This is the first report demonstrating that the exogenous factor antagonizes the VEGF receptor by binding to the exterior face of the receptor and, furthermore, is the first identification of the target molecule of myotoxic basic phospholipase A2 in viper venom. The “Experimental Procedures” section is provided in the supplemental material. Identification of KDR-binding Protein in the Venom of Eastern Cottonmouth—Several snake venoms contain activator and inhibitor toxins that both target the same molecule; some vipers possess blood coagulation factor X activators (12Tans G. Rosing J. Haemostasis. 2001; 31: 225-233PubMed Google Scholar), such as RVV-X, while others include factor X-binding protein, which binds the Gla domain of factor X and prevents blood coagulation (13Mizuno H. Fujimoto Z. Atoda H. Morita T. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 7230-7234Crossref PubMed Scopus (126) Google Scholar). From this point of view, we speculated that some snake venoms might contain VEGF receptor antagonists, in contrast to previously identified snake venom VEGF-like proteins. We screened 29 species of snake venom using an index of blocking activity for the interaction between KDR-IgG and vammin, a snake venom-derived KDR-specific VEGF from the venom of Vipera ammodytes ammodytes. As a result, we detected strong inhibitory activity in the venom of A. piscivorus piscivorus (eastern cottonmouth) with an IC50 of ∼10 μg/ml, in addition to previously identified VEGF-containing venoms, while the venom of Pseudechis australis, an elapid snake, did not affect this assay at all, even at 200 μg/ml (supplemental Fig. 1). By using two successive chromatographic runs, we isolated the inhibitory protein to give a single chain, highly basic protein with a relative molecular mass of 16.8 kDa, hereinafter named KDR-binding protein (KDR-bp) (Fig. 1A). Sequence analysis of N-terminal and enzymatically digested fragments revealed that the peptide sequence of KDR-bp is identical to Lys49-phospholipase A2 (Lys49PLA2), an inactive phospholipase A2 homologue with potent myotoxic activity (GenBank™ accession number: PSSNAM; Fig. 1B). KDR-bp Binds to the Extracellular Domain of VEGF Receptors but Not Those of PDGF or FGF Receptors—To evaluate the affinity of the isolated protein to KDR, kinetic parameters were measured using the Biacore system. KDR-bp bound to both immobilized KDR-IgG and the extracellular domain of KDR (KDRD1–7) with similar affinities (Kd of ∼1 × 10–8 m), while no specific interaction was observed with active Asp49PLA2 from Trimeresurus flavoviridis venom (Tf PLA2), despite the structural similarity (Fig. 2A and Table I). We also tested the binding ability of KDR-bp to other VEGF receptors, Flt-1 (14de Vries C. Escobedo J.A. Ueno H. Houck K. Ferrara N. Williams L.T. Science. 1992; 255: 989-991Crossref PubMed Scopus (1893) Google Scholar), neuropilin-1 (15Soker S. Takashima S. Miao H.Q. Neufeld G. Klagsbrun M. Cell. 1998; 92: 735-745Abstract Full Text Full Text PDF PubMed Scopus (2076) Google Scholar), and Flt-4 (16Joukov V. Pajusola K. Kaipainen A. Chilov D. Lahtinen I. Kukk E. Saksela O. Kalkkinen N. Alitalo K. EMBO J. 1996; 15: 290-298Crossref PubMed Scopus (1153) Google Scholar, 17Achen M.G. Jeltsch M. Kukk E. Makinen T. Vitali A. Wilks A.F. Alitalo K. Stacker S.A. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 548-553Crossref PubMed Scopus (1017) Google Scholar). Specific binding was observed with Flt-1-IgG and the extracellular domain of the Flt-1 (Flt-1D1∼6)-immobilized surface, although the binding affinity was ∼10 times smaller than that of KDR (Kd = 7.4 × 10–8 m, Fig. 2B). In contrast to Flt-1, only slight interaction was observed with neuropilin-1-IgG and the Flt-4-IgG-immobilized surface (Fig. 2C). As the extracellular region of VEGF receptors, including KDR, Flt-1, and Flt-4, is composed of seven tandem immunoglobulin-like domains, we considered the possibility that KDR-bp recognizes a common structural feature of immunoglobulin superfamily proteins, resulting in apparent binding ability to receptor-immunoglobulin chimeric proteins, such as neuropilin-1-IgG and Flt-4-IgG. We therefore evaluated the binding ability to human IgG and the extracellular domains of other growth factor receptors, which are composed of tandem immunoglobulin-like domains that are similar to VEGF receptors. KDR-bp bound to immobilized-human IgG to a smaller extent (Kd = 1.75 × 10–6 m) but did not bind to the extracellular domain of PDGF receptor α at all (supplemental Fig. 2). KDR-bp bound only slightly to PDGF receptor β-IgG and FGF receptor 1a-IgG, with a comparative extent to human IgG, suggesting binding to the IgG portion of chimeric proteins (supplemental Fig. 2). In all binding experiments, specific interaction was only observed with KDR-bp (Lys49PLA2), while we could not detect any specific interaction with Tf PLA2 (Fig. 2 and supplemental Fig. 2). These results strongly indicate that Lys49PLA2 from the venom of eastern cottonmouth is a selective ligand for VEGF receptors, especially KDR.Table IKinetic parameters for binding of KDR-bp to immobilized VEGF receptorskakdissKdm-1·s-1 (× 104)s-1 (× 10-4)m (× 10-8)KDR-bp from A. p. piscivorusKDR-IgG3.443.300.96KDRD1-73.413.421.0Flt-1D1-60.110.847.6IgG0.0468.04175Basic protein I from T. flavoviridisKDRD1-73.032.740.90Flt-1D1-60.211.517.2 Open table in a new tab KDR-bp Inhibits VEGF165-KDR Interaction and Blocking of VEGF165—As expected from the screening in the initial study, purified KDR-bp competitively blocked both VEGF165 and vammin binding to KDR-IgG with an IC50 of ∼2 × 10–6 m (supplemental Fig. 3). Similarly, KDR-bp and KDR-IgG interaction was inhibited by VEGF165 (Fig. 3), indicating that KDR-bp shares the binding epitope on KDR with VEGF165, or alternatively, blocks allosterically by binding to a region distinct from the VEGF165-binding site, such as the fourth immunoglobulin-like domain, which is essential for VEGF165-induced KDR dimerization. We next evaluated the effect of KDR-bp on the biological activity of VEGF165. KDR-bp specifically and completely attenuated the endothelial cell growth stimulated by VEGF165 without toxic effect on cell viability but did not affect fetal serum (5%)-induced cell growth (Fig. 4 and supplemental Fig. 4). These observations indicate that KDR-bp is an antagonistic ligand for KDR. Influence of KDR Binding Ability on Biological Properties of Lys49PLA2s—Snake venom PLA2s are a widespread toxin in most venomous snakes. Several Viperidae snakes possess Lys49PLA2s in their venoms, which are inactive PLA2 homologues, because of substitution of Asp49, a key residue for the binding of essential Ca2+-cofactor, by Lys49, and which exhibit strong myotoxic activity (9Lomonte B. Angulo Y. Calderon L. Toxicon. 2003; 42: 885-901Crossref PubMed Scopus (260) Google Scholar, 10Gutierrez J.M. Ownby C.L. Toxicon. 2003; 42: 915-931Crossref PubMed Scopus (333) Google Scholar). To date, a large number of myotoxic PLA2s from several viper venoms have been isolated and structurally characterized; however, the molecular mechanism of myotoxicity of these inactive PLA2s is poorly understood. We have reported herein that snake venom Lys49PLA2 is an antagonistic ligand for KDR. This result provides further insight into the molecular mechanism of snake venom myotoxicity. It has been reported that heparin could attenuate the myotoxic activity of Lys49PLA2s and that their heparin binding ability and myotoxic activity are completely mediated by the C-terminal portion (9Lomonte B. Angulo Y. Calderon L. Toxicon. 2003; 42: 885-901Crossref PubMed Scopus (260) Google Scholar, 18Nunez C.E. Angulo Y. Lomonte B. Toxicon. 2001; 39: 1587-1594Crossref PubMed Scopus (106) Google Scholar, 19Lomonte B. Angulo Y. Santamaria C. Toxicon. 2003; 42: 307-312Crossref PubMed Scopus (75) Google Scholar). The KDR-bp (Lys49PLA2) we have identified interacted with heparin with a Kd of 4.5 × 10–9 m (supplemental Fig. 5) and has shown that its myotoxic site is located in the C-terminal region (18Nunez C.E. Angulo Y. Lomonte B. Toxicon. 2001; 39: 1587-1594Crossref PubMed Scopus (106) Google Scholar). Heparin is known to greatly modulate VEGF-VEGF receptor interaction, particularly that of VEGF165-KDR (20Tessler S. Rockwell P. Hicklin D. Cohen T. Levi B.Z. Witte L. Lemischka I.R. Neufeld G. J. Biol. Chem. 1994; 269: 12456-12461Abstract Full Text PDF PubMed Google Scholar, 21Keyt B.A. Berleau L.T. Nguyen H.V. Chen H. Heinsohn H. Vandlen R. Ferrara N. J. Biol. Chem. 1996; 271: 7788-7795Abstract Full Text Full Text PDF PubMed Scopus (532) Google Scholar). In addition, Lys49PLA2s were shown to form a Ca2+-independent homodimer in aqueous solution and to exhibit dimerization-dependent myotoxic activity (22de Oliveira A.H. Giglio J.R. Andriao-Escarso S.H. Ito A.S. Ward R.J. Biochemistry. 2001; 40: 6912-6920Crossref PubMed Scopus (51) Google Scholar). For these aspects, both KDR-bp and VEGF165 have very similar ligand properties, despite their opposite biological effects. Lys49PLA2s from the venom of the Habu snake (T. flavoviridis), basic protein I and basic protein II, were shown to induce apoptosis in HL-60 promyelomonocytic leukemia cells but not in Tf PLA2, an active PLA2 derived from same venom. 2N. Oda-Ueda, D. Tsuru, and M. Ohno, presented at the XIIIth World Congress of the International Society of Toxinology, 2000, Paris, France, Abstract No. L87. Similar Lys49PLA2-induced apoptosis was observed on a lymphoblastoid cell line CRL-8062 (23Mora R. Valverde B. Diaz C. Lomonte B. Gutierrez J.M. Toxicon. 2005; 45: 651-660Crossref PubMed Scopus (45) Google Scholar). It is well established that KDR is functional on some VEGF-producing leukemias, including HL-60 cells, resulting in the formation of a VEGF/KDR autocrine loop, which mediates their proliferation and survival (24Dias S. Hattori K. Zhu Z. Heissig B. Choy M. Lane W. Wu Y. Chadburn A. Hyjek E. Gill M. Hicklin D.J. Witte L. Moore M.A. Rafii S. J. Clin. Invest. 2000; 106: 511-521Crossref PubMed Scopus (413) Google Scholar, 25Dias S. Shmelkov S.V. Lam G. Rafii S. Blood. 2002; 99: 2532-2540Crossref PubMed Scopus (225) Google Scholar). Taking our findings into consideration, Lys49PLA2-mediated apoptosis in leukemic cells could be explained by its KDR-blocking property. In fact, both basic protein I and basic protein II interacted with the extracellular domain of KDR with similar affinities compared with KDR-bp (Table I). These data also suggest that KDR-binding ability is a general characteristic of Lys49PLA2s in several snake venoms. However, it is unclear whether the KDR binding property is directly involved in its myotoxicity and, furthermore, why KDR-bp/Lys49PLA2 is myotoxic but not toxic for other cell types, despite their expression of KDR. KDR-bp/Lys49PLA2 may affect another unidentified molecule that is specifically expressed on skeletal muscle cells and leads to its myotoxicity, although further experiments would be required to investigate this. KDR-bp also bound to IgG, but not to the extracellular domains of PDGF or FGF receptors, which are composed of tandem immunoglobulin-like domains similar to KDR and Flt-1. It is unclear whether the binding to IgG is a biologically important event in envenoming or not. Several animals, such as hedgehogs and mongoose, have toxin-neutralizing proteins in their blood. An anti-myotoxic protein, DM64, was isolated from the serum of southern opossum (Didelphis marsupialis), which is composed of five immunoglobulin-like domains. DM64 forms a noncovalent complex with snake venom-derived myotoxic PLA2 (myotoxin II/Lys49PLA2 from Bothrops asper venom) and neutralizes its myotoxicity (26Rocha S.L. Lomonte B. Neves-Ferreira A.G. Trugilho M.R. Junqueirade-Azevedo Ide L. Ho P.L. Domont G.B. Gutierrez J.M. Perales J. Eur. J. Biochem. 2002; 269: 6052-6062Crossref PubMed Scopus (45) Google Scholar). These facts suggest that snake venom Lys49PLA2 may recognize a specific structural motif present in some of the immunoglobulin superfamily proteins. At the present, we could not confirm the reactive site of KDR-bp on KDR binding. Crystal structural studies reveal that the overall structure of Lys49PLA2 is quite similar to that Asp49PLA2 (27Holland D.R. Clancy L.L. Muchmore S.W. Ryde T.J. Einspahr H.M. Finzel B.C. Heinrikson R.L. Watenpaugh K.D. J. Biol. Chem. 1990; 265: 17649-17656Abstract Full Text PDF PubMed Google Scholar). In addition, it is reported that the replacement of Lys49 of Lys49PLA2 to Asp does not reduce its myotoxic activity at all (11Ward R.J. Chioato L. de Oliveira A.H. Ruller R. Sa J.M. Biochem. J. 2002; 362: 89-96Crossref PubMed Scopus (78) Google Scholar). Considering these facts, we speculate that KDR binding properties of Lys49PLA2 are also not directly on the at although it is unknown whether KDR binding ability is involved in its myotoxicity or not. In this study, we identified Lys49PLA2s from the venom of eastern cottonmouth as an antagonistic ligand for KDR with subnanomolar affinity and also identified Lys49PLA2s from another snake venom. In addition to its unique KDR-bp is a of eastern cottonmouth venom be obtained at a of of venom for these aspects, it is to other that KDR is also expressed on skeletal muscle cells, although the physiological role of skeletal muscle KDR remains muscle KDR some distinct properties from KDR expressed on endothelial cells, it to some extent A. A. A. S. C. P. P. J. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar). Our offers insight into the as yet unknown mechanism of myotoxic activity of snake venom Furthermore, KDR-bp is a valuable tool in the of the structure and function of KDR. We are to Takani for on some of the We also and for their with
25
Marc G. Achen, Michael Jeltsch, Eola Kukk et al. · Proceedings of the National Academy of Sciences · 1998 · 1.2K citations